_256_384.jpg)
News | December 08, 2021
IPM registers 6 % yoy revenue growth in Nov 2021.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
The fund aims at investing in companies that extends human healthspan
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
The ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Subscribe To Our Newsletter & Stay Updated
